BMS 986226

Drug Profile

BMS 986226

Alternative Names: BMS-986226

Latest Information Update: 23 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 31 Aug 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (IV) (NCT03251924)
  • 31 Aug 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA (IV) (NCT03251924)
  • 22 Aug 2017 Bristol-Myers Squibb plans a phase I/II trial of BMS 986226 in combination with nivolumab or ipilimumab for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in USA and Canada in August 2017 (NCT03251924)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top